1-2 of 2
Lamya AIT SI Selmi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux
Journal: Blood
Blood (2023) 142 (Supplement 1): 2923.
https://doi.org/10.1182/blood-2023-185609
Published: 2023
Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Marie Sebert, Thomas Cluzeau, Odile Beyne Rauzy, Aspasia Stamatoulas Bastard, Sophie Dimicoli-Salazar, Sylvain Thepot, Pierre Peterlin, Sophie Park, Marie-Pierre Gourin, Oana Brehar, Cécile Bally, Sébastien Maury, Gaelle Fossard, Lamya Ait Si Selmi, Cendrine Chaffaut, Emmanuelle Clappier, Raphael Itzykson, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux, Lionel Ades
Journal: Blood
Blood (2021) 138 (Supplement 1): 62.
https://doi.org/10.1182/blood-2021-146932
Published: 2021